MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Windtree Therapeutics Net Income 2011-2026 | WINT
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Windtree Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.79 M | -20.3 M | -39.2 M | -67.6 M | -32.6 M | -27.5 M | -20.5 M | -18.4 M | -39.5 M | -55.2 M | -44.1 M | -45.2 M | -37.3 M | -21 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.79 M | -67.6 M | -33.6 M |
Quarterly Net Income Windtree Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.1 M | -10.6 M | -4.04 M | - | -2.75 M | -12 M | 10.2 M | - | -4.42 M | -6.6 M | -4.11 M | - | -4.06 M | -17.3 M | -8.13 M | - | -8.21 M | -37.4 M | -8.96 M | - | -9.02 M | -9.56 M | -6.53 M | -7.38 M | -7.13 M | -6.44 M | -6.54 M | -9.04 M | -3.93 M | -3.05 M | -4.51 M | 2.47 M | -5.44 M | -6.75 M | -8.72 M | -6.6 M | -8.36 M | -10.6 M | -13.9 M | -10.1 M | -21.6 M | -11.3 M | -12.2 M | -10.6 M | -11.3 M | -10.6 M | -11.5 M | -11.7 M | -12.2 M | -8.63 M | -12.6 M | -6.82 M | -13.3 M | -7.14 M | -10 M | -4.3 M | -4.75 M | -8.08 M | -3.84 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | -37.4 M | -8.89 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
-230 M | $ 3.83 | 1.32 % | $ 105 M |  Schweiz |
 |
Agenus
AGEN
|
-3.08 M | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
-413 M | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
-5.34 M | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.95 | -11.63 % | $ 266 B |  Britain |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aldeyra Therapeutics
ALDX
|
-33.8 M | $ 1.57 | -5.42 % | $ 94.3 M | USA |
 |
Aligos Therapeutics
ALGS
|
-24.2 M | $ 8.08 | 1.38 % | $ 79.9 M | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
-88.1 M | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-102 M | $ 1.99 | 0.81 % | $ 107 M | USA |
 |
Amgen
AMGN
|
7.71 B | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
72.1 M | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
-82.7 M | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
-18.5 M | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Annexon
ANNX
|
-207 M | $ 5.56 | 1.0 % | $ 862 M | USA |
 |
Annovis Bio
ANVS
|
-28.9 M | $ 2.56 | 12.28 % | $ 52.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 0.88 | -5.16 % | $ 4.8 M | China |
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Aprea Therapeutics
APRE
|
-12.6 M | $ 0.7 | -1.87 % | $ 4.58 M | USA |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Ardelyx
ARDX
|
-61.6 M | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
argenx SE
ARGX
|
-408 M | $ 749.99 | 0.48 % | $ 25 B |  Niderland |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
-80.8 M | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Assembly Biosciences
ASMB
|
-6.12 M | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.62 | 1.82 % | $ 8.71 B |  Australia |